Last edition
News about "SURMOUNT-MAINTAIN trial"
Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials
Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.
SURMOUNT-MAINTAIN Trial | 13/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members